Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.79 |
| ▸ | TAF1 | P21675 | 12/20 | 0.79 |
| ▸ | PLK1 | P53350 | 7/20 | 0.64 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379525 | 1.00 | BRD4 (0.79) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17839900 | 1.00 | BRD4 (0.79) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17891484 | 0.99 | BRD4 (0.78) | BRD4TAF1PLK1BRDT | |
| SCHEMBL15825339 | 0.99 | BRD4 (0.78) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17854802 | 0.93 | BRD4 (0.78) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17891511 | 0.93 | BRD4 (0.78) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17891606 | 0.92 | BRD4 (0.80) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17884564 | 0.92 | BRD4 (0.77) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17891600 | 0.92 | BRD4 (0.78) | BRD4TAF1PLK1BRDT | |
| SCHEMBL17891545 | 0.92 | BRD4 (0.78) | BRD4TAF1PLK1BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | claimed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | BRD4 941/4885TAF1 1385/4885PLK1 1349/4885 |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BRD4, BET1, BRDT | BRD4 1/4885TAF1 288/4885PLK1 793/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | BRD4 687/4885TAF1 3700/4885PLK1 838/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | BRD4 1674/4885TAF1 1290/4885PLK1 3075/4885 |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885TAF1 3700/4885PLK1 838/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | BRD4 941/4885TAF1 1385/4885PLK1 1349/4885 |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885TAF1 3700/4885PLK1 838/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885TAF1 3700/4885PLK1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.